Yorktown Management & Research Co Inc Purchases Shares of 5,550 Guardant Health, Inc. $GH

Yorktown Management & Research Co Inc purchased a new stake in Guardant Health, Inc. (NASDAQ:GH) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 5,550 shares of the company’s stock, valued at approximately $289,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Jennison Associates LLC bought a new position in Guardant Health in the second quarter valued at approximately $37,233,000. Mendel Money Management bought a new position in Guardant Health in the second quarter valued at approximately $253,000. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in Guardant Health by 403.4% in the second quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 45,324 shares of the company’s stock valued at $2,359,000 after buying an additional 36,320 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in Guardant Health in the second quarter valued at approximately $2,382,000. Finally, Envestnet Asset Management Inc. lifted its stake in Guardant Health by 40.5% in the second quarter. Envestnet Asset Management Inc. now owns 38,622 shares of the company’s stock valued at $2,010,000 after buying an additional 11,125 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Insiders Place Their Bets

In related news, Director Medina Manuel Hidalgo sold 2,165 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $54.16, for a total transaction of $117,256.40. Following the transaction, the director directly owned 851 shares in the company, valued at approximately $46,090.16. The trade was a 71.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Helmy Eltoukhy sold 300,000 shares of the company’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the completion of the transaction, the chief executive officer owned 2,123,499 shares in the company, valued at approximately $126,242,015.55. This represents a 12.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 302,691 shares of company stock worth $17,984,628. 6.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

GH has been the topic of a number of research reports. Mizuho boosted their price objective on shares of Guardant Health from $65.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, September 25th. Stifel Nicolaus set a $73.00 price objective on shares of Guardant Health in a research report on Thursday, September 25th. Wolfe Research raised shares of Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 price objective on the stock in a research report on Thursday, September 25th. Piper Sandler boosted their price objective on shares of Guardant Health from $60.00 to $90.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Finally, Wells Fargo & Company initiated coverage on shares of Guardant Health in a research report on Monday, September 22nd. They issued an “overweight” rating and a $72.00 price objective on the stock. Twenty-three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $67.29.

Guardant Health Trading Down 1.8%

Shares of GH opened at $69.58 on Wednesday. The company has a market cap of $8.68 billion, a price-to-earnings ratio of -20.77 and a beta of 1.53. Guardant Health, Inc. has a 1-year low of $21.28 and a 1-year high of $73.31. The company’s fifty day simple moving average is $62.70 and its 200 day simple moving average is $52.34.

Guardant Health (NASDAQ:GH) last issued its earnings results on Wednesday, July 30th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.08. The firm had revenue of $232.09 million for the quarter, compared to analyst estimates of $211.19 million. Guardant Health’s quarterly revenue was up 31.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.84) earnings per share. As a group, research analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.